Follicular Lymphoma Excellence Forum

Follicular Lymphoma

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Videos

Circulating Tumor DNA and Prediction of Early Progression in Follicular Lymphoma

04/13/2023

Margarita Sánchez-Beato, PhD, discusses the monitoring of circulating tumor DNA to predict response to treatment and early progression among patients with follicular lymphoma.

Margarita Sánchez-Beato, PhD,...

04/13/2023

Oncology

Quiz

Quiz: Triplet Therapy Combination for R/R Follicular Lymphoma

03/23/2023

True or False: The triplet therapy combination of epcoritamab and rituximab and lenalidomide was active in patients with R/R follicular lymphoma, including those who might be more difficult to treat, such as refractory patients and those who...

True or False: The triplet...

03/23/2023

Oncology

Quiz

Quiz: Epcoritamab Plus Rituximab and Lenalidomide Treatment for Relapsed/Refractory Follicular Lymphoma

03/23/2023

True or False: In a study exploring subcutaneous epcoritamab combined with rituximab and lenalidomide treatment for patients with relapsed/refractory follicular lymphoma, the majority of patients who had a partial response at first assessment...

True or False: In a study...

03/23/2023

Oncology

Matthew Matasar, MD, Rutgers Cancer Institute of New Jersey

Videos

Mosunetuzumab Demonstrates Favorable Efficacy and Tolerability in Relapsed/Refractory Follicular Lymphoma

11/16/2022

Matthew Matasar, MD, discusses a phase 2 study assessing the safety and efficacy of fixed-duration mosunetuzumab, a CD20-CD3 T-cell-engaging bispecific monoclonal antibody, for relapsed/refractory follicular lymphoma.

Matthew Matasar, MD, discusses a...

11/16/2022

Oncology

Videos

Subcutaneous Epcoritamab With Rituximab and Lenalidomide for Relapsed/Refractory Follicular Lymphoma

11/02/2022

Lorenzo Falchi, MD, presents updated findings from a phase 1/2 trial exploring subcutaneous epcoritamab combined with rituximab and lenalidomide for patients with relapsed/refractory follicular lymphoma.

Lorenzo Falchi, MD, presents...

11/02/2022

Oncology

Sarah Rutherford, MD, Weill Cornell Medicine

Videos

CAR-T Therapy vs Other Novel Agents for Third-Line Treatment of FL

05/22/2022

Sarah Rutherford, MD, debates why she believes CAR-T therapy is the preferred treatment for patients with early progressing FL after 2 lines of prior therapy.

Sarah Rutherford, MD, debates...

05/22/2022

Oncology

Videos

Long-term Safety of Rituximab Biosimilar in Untreated Advanced FL

04/07/2022

Christian Buske, MD, overviews a phase 3 study on the long-term safety and efficacy of CT-P10, a rituximab biosimilar, in patients with untreated advanced FL.

Christian Buske, MD, overviews a...

04/07/2022

Oncology

Carla Casulo, MD, Wilmot Cancer Institute, University of Rochester

Podcasts

Treatment Options for Managing Patients With Newly Diagnosed or Relapsed FL

03/25/2022

Carla Casulo, MD, overviews the various treatments that have been approved for the management of patients with newly diagnosed and relapsed FL.

Carla Casulo, MD, overviews the...

03/25/2022

Oncology

Craig Portell, MD, University of Virginia Health

Videos

Frontline Venetoclax Plus Obinutuzimab and Bendamustine for Patients With High Tumor Burden FL

03/23/2022

Craig A Portell, MD, talks about a phase 2 study of venetoclax in combination with obinutuzumab and bendamustine for patients with high tumor burden FL as frontline therapy.

Craig A Portell, MD, talks about...

03/23/2022

Oncology

Podcasts

Tazemetostat Plus Lenalidomide and Rituximab for Relapsed/Refractory FL: Promising Data From SYMPHONY-1 Trial

03/21/2022

Connie Batlevi, MD, PhD, shares updated safety and efficacy data from the SYMPHONY-1 trial of tazemetostat, a first-class oral selective EZH2 inhibitor, for patients with FL.

Connie Batlevi, MD, PhD, shares...

03/21/2022

Oncology

Recent News

Commentary

Challenges of Managing FL: A Focus on PI3K Inhibitors and Next-Line Therapy

04/26/2020

Elizabeth Brem, MD, discusses some of the challenges with managing FL, focusing on the incorporation of PIK3 kinase inhibitors in the treatment of these patients.

Elizabeth Brem, MD, discusses...

04/26/2020

Oncology

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology